Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia
diseaseOn this page
Also known as NEDBASH
Summary
Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia (MONDO:0032878) is a disease caused by NTNG2 (GenCC Strong), with 4 cohort genes.
At a glance
- Causal gene: NTNG2 (GenCC Strong)
- Cohort genes: 4
- ClinVar variants: 19
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia |
| Mondo ID | MONDO:0032878 |
| OMIM | 618718 |
| UMLS | C5231471 |
| MedGen | 1684663 |
| Is cancer (heuristic) | no |
Also known as: NEDBASH
Data availability: 19 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary neurological disease › Mendelian neurodevelopmental disorder › neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia
Related subtypes (275): microcephaly and chorioretinopathy, microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability, autosomal dominant primary microcephaly, Prader-Willi syndrome, Smith-Magenis syndrome, microcephalic osteodysplastic primordial dwarfism type I, microcephalic osteodysplastic primordial dwarfism type II, microcephalic osteodysplastic primordial dwarfism, type 3, CK syndrome, orofaciodigital syndrome I, Rett syndrome, Wieacker-Wolff syndrome, Amish lethal microcephaly, cerebral palsy, spastic quadriplegic, 2, Pitt-Hopkins-like syndrome 2, developmental delay with autism spectrum disorder and gait instability, complex cortical dysplasia with other brain malformations 5, AHDC1-related intellectual disability - obstructive sleep apnea - mild dysmorphism syndrome, intellectual disability, autosomal dominant 29, Au-Kline syndrome, cerebellar atrophy, visual impairment, and psychomotor retardation;, neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, cerebral palsy, spastic quadriplegic, 3, Okur-Chung neurodevelopmental syndrome, Harel-Yoon syndrome, neurodevelopmental disorder with hypotonia, seizures, and absent language, alternating hemiplegia of childhood, autosomal recessive primary microcephaly, Rubinstein-Taybi syndrome, neurodevelopmental disorder with cerebellar atrophy and with or without seizures, neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, neurodevelopmental disorder with hypotonia, microcephaly, and seizures, neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures, neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity, neurodevelopmental disorder with language impairment and behavioral abnormalities, neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities, neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities, neurodevelopmental disorder with or without early-onset generalized epilepsy, neurodevelopmental disorder with or without autism or seizures, neurodevelopmental disorder with cerebral atrophy and variable facial dysmorphism, neurodevelopmental disorder with dysmorphic facies and variable seizures, squalene synthase deficiency, intellectual developmental disorder and retinitis pigmentosa; IDDRP, neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, Houge-Janssens syndrome 3, neurodevelopmental disorder with central and peripheral motor dysfunction, neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination, neurodevelopmental disorder with impaired speech and hyperkinetic movements, developmental delay with variable intellectual impairment and behavioral abnormalities, neurodevelopmental disorder with or without variable brain abnormalities; NEDBA, neurodevelopmental disorder with seizures and speech and walking impairment, neurodevelopmental disorder with microcephaly and structural brain anomalies, neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities, neurodevelopmental disorder with visual defects and brain anomalies, neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, neurodevelopmental disorder with cerebellar hypoplasia and spasticity, neurodevelopmental disorder with structural brain anomalies and dysmorphic facies, neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, neurodevelopmental disorder with spastic quadriplegia, optic atrophy, seizures, and structural brain anomalies, neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, neurodevelopmental disorder with absent language and variable seizures, neurodevelopmental disorder with nonspecific brain abnormalities and with or without seizures, neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity, neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, Poirier-Bienvenu neurodevelopmental syndrome, neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy, neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements, neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, neurodevelopmental disorder with microcephaly and dysmorphic facies, neurodevelopmental disorder with relative macrocephaly and with or without cardiac or endocrine anomalies, neurodevelopmental disorder with dysmorphic facies, impaired speech, and hypotonia, neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, neurodevelopmental disorder with speech impairment and dysmorphic facies, neurodevelopmental disorder with alopecia and brain abnormalities, neurodevelopmental disorder with seizures and brain atrophy, neurodevelopmental disorder with microcephaly, seizures, and brain atrophy, Delpire-McNeill syndrome, neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, developmental delay and seizures with or without movement abnormalities, Stankiewicz-Isidor syndrome, neurodevelopmental disorder with midbrain and hindbrain malformations, neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, neurodevelopmental disorder with involuntary movements, neurodevelopmental disorder with hypotonia, neuropathy, and deafness, neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities, neurodevelopmental disorder with microcephaly, ataxia, and seizures, neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, neurodevelopmental disorder with severe motor impairment and absent language, neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter, neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, neurodevelopmental disorder with or without seizures and gait abnormalities, neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features, neurodevelopmental disorder with poor language and loss of hand skills, neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures, neurodevelopmental disorder with spasticity and poor growth, neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, FOXG1 disorder, genetic developmental and epileptic encephalopathy, X-linked complex neurodevelopmental disorder, PPP2R1A-related intellectual disability, intellectual disability, autosomal dominant, CACNA1A-related complex neurodevelopmental disorder, X-linked intellectual disability, PAX5-related B lymphopenia and autism spectrum disorder, neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, KCNH1 associated disorder, AFG2B-related complex neurodevelopmental disorder with motor features and hearing loss, intellectual disability, autosomal recessive, FAT4-related neurodevelopmental disorder, SOX11-related complex neurodevelopmental disorder with or without congenital anomalies, microcephaly with lissencephaly and/or hydranencephaly, MYH10-related neurodevelopmental disorder with congenital anomalies, CNOT9-related developmental disorder with seizures, HMGB1-related brachyphalangy, polydactyly and tibial aplasia syndrome, ATXN7L3-related developmental delay, hypotonia and facial dysmorphism, DIP2C-related developmental disorder with speech delay, EPB41L3-related developmental disorder with delayed myelination and seizures, GABRA4-related neurodevelopmental disorder with seizures, GABRD-related neurodevelopmental disorder with epilepsy, KCNK3-related developmental delay with sleep apnea, RFX3-related neurodevelopmental disorder with autism and other behavioural abnormalities, RFX4-related neurodevelopmental disorder with autism and other behavioural abnormalities, KDM2B-related neurodevelopmental disorder, TRA2B-related neurodevelopmental disorder, WDR5-related neurodevelopmental disorder, ARF3-related neurodevelopmental disorder, CBX1-related neurodevelopmental disorder, DDX17-related neurodevelopmental disorder, FEZF2-related neurodevelopmental disorder, HDAC3-related neurodevelopmental disorder, DEAF1-associated neurodevelopmental disorder, SYNCRIP-related neurodevelopmental disorder, HNRNPC-related neurodevelopmental disorder, NACC1-related neurodevelopmental disorder with epilepsy, cataracts and episodic irritability, SETD2-related neurodevelopmental disorder without or with macrocephaly/overgrowth, neurodevelopmental disorder with gait disturbance, dysmorphic facies, and behavioral abnormalities, X-linked, Alzahrani-Kuwahara syndrome, neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia, Hiatt-Neu-Cooper neurodevelopmental syndrome, neurodevelopmental disorder with seizures and gingival overgrowth, neurodevelopmental disorder with cerebellar atrophy and motor dysfunction, neurodevelopmental disorder with infantile epileptic spasms, neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, neurodevelopmental disorder with motor and speech delay and behavioral abnormalities, neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, neurodevelopmental disorder with hypotonia and dysmorphic facies, neurodevelopmental disorder with hypotonia and brain abnormalities, neurodevelopmental disorder with impaired language and ataxia and with or without seizures, neurodevelopmental disorder with hearing loss and spasticity, neurodevelopmental disorder with hypotonia and gross motor and speech delay, neurodevelopmental disorder with hyperkinetic movements and dyskinesia, neurodevelopmental disorder, nonprogressive, with spasticity and transient opisthotonus, Marbach-Schaaf neurodevelopmental syndrome, neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, Brunet-Wagner neurodevelopmental syndrome, Ferguson-Bonni neurodevelopmental syndrome, neurodevelopmental disorder with or without variable movement or behavioral abnormalities, neurodevelopmental disorder with central hypotonia and dysmorphic facies, neurodevelopmental disorder with neuromuscular and skeletal abnormalities, Chilton-Okur-Chung neurodevelopmental syndrome, neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abnormalities, parenti-mignot neurodevelopmental syndrome, neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures, Dentici-Novelli neurodevelopmental syndrome, neurodevelopmental disorder with poor growth and skeletal anomalies, neurodevelopmental disorder with language delay and seizures, neurodevelopmental disorder with dystonia and seizures, Dworschak-Punetha neurodevelopmental syndrome, neurodevelopmental disorder with epilepsy and brain atrophy, neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy, neurodevelopmental disorder with speech delay and variable ocular anomalies, neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies, neurodevelopmental disorder with spasticity, seizures, and brain abnormalities, neurodevelopmental disorder with microcephaly, movement abnormalities, and seizures, neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, neurodevelopmental disorder with microcephaly, short stature, and speech delay, neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment, neurodevelopmental disorder with short stature, prominent forehead, and feeding difficulties, neurodevelopmental disorder with dysmorphic facies and skeletal and brain abnormalities, neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-pelger-huet anomaly, neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects, neurodevelopmental disorder with eye movement abnormalities and ataxia, neurodevelopmental disorder with growth retardation, dysmorphic facies, and corpus callosum abnormalities, neurodevelopmental disorder with speech impairment and with or without seizures, neurodevelopmental disorder with hypotonia, dysmorphic facies, and skin abnormalities, neurodevelopmental disorder with poor growth, large ears, and dysmorphic facies, neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia, neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, neurodevelopmental disorder with poor growth and behavioral abnormalities, neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum, neurodevelopmental disorder with absent speech and movement and behavioral abnormalities, neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures, neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities, neurodevelopmental disorder with intracranial hemorrhage, seizures, and spasticity, neurodevelopmental disorder with motor and language delay, ocular defects, and brain abnormalities, neurodevelopmental disorder with microcephaly and movement abnormalities, neurodevelopmental disorder with hypotonia and speech delay, with or without seizures, neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities, neurodevelopmental disorder with impaired language, behavioral abnormalities, and dysmorphic facies, neurodevelopmental disorder with language delay and variable cognitive abnormalities, neurodevelopmental disorder with motor regression, progressive spastic paraplegia, and oromotor dysfunction, Hao-Fountain syndrome due to USP7 mutation, neurodevelopmental disorder with motor abnormalities, seizures, and facial dysmorphism, neurodevelopmental disorder with hyperkinetic movements, seizures, and structural brain abnormalities, neurodevelopmental disorder with hypotonia and characteristic brain abnormalities, neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, Jeffries-Lakhani neurodevelopmental syndrome, neurodevelopmental disorder with language impairment, autism, and attention deficit-hyperactivity disorder, neurodevelopmental disorder plus optic atrophy, neurodevelopmental disorder with progressive movement abnormalities, aplasia cutis-enamel dysplasia syndrome, neurodevelopmental disorder with hypotonia and seizures, El Hayek-Chahrour neurodevelopmental disorder, neurodevelopmental disorder with hypotonia, feeding difficulties, facial dysmorphism, and brain abnormalities, neurodevelopmental disorder with hypotonia, brain anomalies, distinctive facies, and absent language, otofacial neurodevelopmental syndrome, neurodevelopmental disorder with characteristic facial and ectodermal features and tetraparesis 1, Kariminejad neurodevelopmental syndrome, Karayol-Borroto-Haghshenas neurodevelopmental syndrome, neurodevelopmental disorder with dysmorphic facies, absent speech and ambulation, and brain abnormalities, neurodevelopmental disorder with variable familial hypercholanemia, intellectual developmental disorder with polymicrogyria and seizures, neurodevelopmental disorder with speech or visual impairment and brain hypomyelination, neurodevelopmental disorder with microcephaly, absent speech, and hypotonia, neurodevelopmental disorder with hypotonia, poor growth, dysmorphic facies, and agammaglobulinemia, neurodevelopmental disorder with progressive spasticity and brain abnormalities, neurodevelopmental disorder with thin corpus callosum, hypotonia, and absent language, neurodevelopmental disorder with white matter abnormalities and gait disturbance, neurodevelopmental disorder with poor growth, seizures, and brain abnormalities, neurodevelopmental disorder with poor or absent speech, dysmorphic facies, and behavioral abnormalities, neurodevelopmental disorder with ataxia and brain abnormalities, neurodevelopmental disorder with dysmorphic facies, brain anomalies, and seizures, Li-Takada-Miyake syndrome, neurodevelopmental disorder with behavioral, ear, and skeletal abnormalities, Nil-Deshwar neurodevelopmental syndrome, Popov-Chang syndrome, neurodevelopmental disorder with achalasia, polyneuropathy, and alacrima, Dursun-Ozgul neurodevelopmental syndrome, neurodevelopmental disorder with growth impairment, quadriparesis, and poor or absent speech, neurodevelopmental disorder with speech delay and behavioral abnormalities, Harel-Tora neurodevelopmental syndrome, neurocardiorenal malformation syndrome, neurodevelopmental disorder with behavioral abnormalities and childhood-onset spastic paraplegia, neurodevelopmental disorder with early-onset seizures, facial dysmorphism, and behavioral abnormalities, neurodevelopmental disorder with structural brain abnormalities and craniofacial abnormalities, Ramond-Elliott neurodevelopmental syndrome, microcephaly, progressive, with simplified gyral pattern and cerebellar hypoplasia, neurodevelopmental disorder with hypotonia, epilepsy, and absent speech, neurodevelopmental disorder with speech delay, movement abnormalities, and seizures, neurodevelopmental disorder with spasticity, thin corpus callosum, and decreased brain white matter, neurodevelopmental disorder with congenital cardiac defects and variable renal and ocular abnormalities, neurodevelopmental disorder with seizures, hypotonia, and variable spasticity, PIP5K1C-related neurodevelopmental disorder, KCND2-related neurodevelopmental disorder with or without seizures, PRPF19-related neurodevelopmental disorder, CTR9-related neurodevelopmental disorder, CAMK2D-related neurodevelopmental disorder and dilated cardiomyopathy, PPFIA3-related neurodevelopmental disorder, dyneinopathy, MYCBP2-related developmental delay with corpus callosum defects, GRIN-related complex neurodevelopmental disorder, RNU5B-1 related neurodevelopmental disorder with seizures and joint laxity, TSEN2-related neurodevelopmental disorder with or without thrombotic microangiopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
19 retrieved; paginated sample, class counts are floors:
8 uncertain significance, 4 pathogenic/likely pathogenic, 3 benign, 2 pathogenic, 1 conflicting classifications of pathogenicity, 1 likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 4292836 | NM_032536.4(NTNG2):c.483G>A (p.Trp161Ter) | NTNG2 | Pathogenic | criteria provided, single submitter |
| 690370 | NM_032536.4(NTNG2):c.376dup (p.Ser126fs) | NTNG2 | Pathogenic | no assertion criteria provided |
| 691555 | NM_032536.4(NTNG2):c.1367G>A (p.Cys456Tyr) | NTNG2 | Pathogenic/Likely pathogenic | no assertion criteria provided |
| 691556 | NM_032536.4(NTNG2):c.319T>G (p.Trp107Gly) | NTNG2 | Pathogenic/Likely pathogenic | no assertion criteria provided |
| 691558 | NM_032536.4(NTNG2):c.1065C>G (p.Cys355Trp) | NTNG2 | Pathogenic/Likely pathogenic | no assertion criteria provided |
| 691559 | NM_032536.4(NTNG2):c.242G>A (p.Cys81Tyr) | NTNG2 | Pathogenic/Likely pathogenic | no assertion criteria provided |
| 691561 | NM_032536.4(NTNG2):c.599C>T (p.Ser200Leu) | NTNG2 | Likely pathogenic | no assertion criteria provided |
| 1012219 | NM_032536.4(NTNG2):c.858-13G>A | NTNG2 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1012220 | NM_032536.4(NTNG2):c.1425C>G (p.Cys475Trp) | NTNG2 | Uncertain significance | criteria provided, single submitter |
| 1705608 | NM_032536.4(NTNG2):c.1058G>A (p.Cys353Tyr) | NTNG2 | Uncertain significance | criteria provided, single submitter |
| 2500771 | NM_032536.4(NTNG2):c.964A>C (p.Asn322His) | NTNG2 | Uncertain significance | criteria provided, single submitter |
| 3242032 | NM_032536.4(NTNG2):c.943G>T (p.Asp315Tyr) | NTNG2 | Uncertain significance | criteria provided, single submitter |
| 3778750 | NM_032536.4(NTNG2):c.914G>A (p.Cys305Tyr) | NTNG2 | Uncertain significance | criteria provided, single submitter |
| 691560 | NM_032536.4(NTNG2):c.446T>C (p.Met149Thr) | NTNG2 | Uncertain significance | criteria provided, single submitter |
| 2585489 | NM_002576.5(PAK1):c.941A>G (p.Asn314Ser) | PAK1 | Uncertain significance | criteria provided, single submitter |
| 4278069 | NM_001136139.4(TCF3):c.1651A>G (p.Asn551Asp) | TCF3 | Uncertain significance | criteria provided, single submitter |
| 1222197 | NM_032536.4(NTNG2):c.738C>T (p.Phe246=) | NTNG2 | Benign | criteria provided, multiple submitters, no conflicts |
| 1278426 | NM_032536.4(NTNG2):c.876C>T (p.His292=) | NTNG2 | Benign | criteria provided, multiple submitters, no conflicts |
| 1327005 | NM_032536.4(NTNG2):c.1036A>G (p.Thr346Ala) | NTNG2 | Benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 6 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| NTNG2 | Strong | Autosomal recessive | neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia | 6 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| NTNG2 | Orphanet:528084 | Non-specific syndromic intellectual disability |
| TCF3 | Orphanet:33110 | Autosomal non-syndromic agammaglobulinemia |
| TCF3 | Orphanet:585956 | B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3) |
| TCF3 | Orphanet:641375 | B-lymphoblastic leukemia/lymphoma with t(17;19) |
Cohort genes → proteins
4 cohort genes, 4 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 4 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| NTNG2 | HGNC:14288 | ENSG00000196358 | Q96CW9 | Netrin-G2 | gencc,clinvar |
| TCF3 | HGNC:11633 | ENSG00000071564 | P15923 | Transcription factor E2-alpha | clinvar |
| TCF7L1 | HGNC:11640 | ENSG00000152284 | Q9HCS4 | Transcription factor 7-like 1 | clinvar |
| PAK1 | HGNC:8590 | ENSG00000149269 | Q13153 | Serine/threonine-protein kinase PAK 1 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| NTNG2 | Netrin-G2 | Involved in controlling patterning and neuronal circuit formation at the laminar, cellular, subcellular and synaptic levels. |
| TCF3 | Transcription factor E2-alpha | Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition. |
| TCF7L1 | Transcription factor 7-like 1 | Participates in the Wnt signaling pathway. |
| PAK1 | Serine/threonine-protein kinase PAK 1 | Protein kinase involved in intracellular signaling pathways downstream of integrins and receptor-type kinases that plays an important role in cytoskeleton dynamics, in cell adhesion, migration, proliferation, apoptosis, mitosis, and in ves… |
Protein-family classification
Druggable: 1 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.25
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Kinase | 1 | 6.9× | 0.410 |
| Transcription factor | 1 | 2.1× | 0.605 |
| Other/Unknown | 2 | 0.9× | 0.769 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| NTNG2 | Other/Unknown | no | EGF, LE_dom, Laminin_N | |
| TCF3 | Transcription factor | no | bHLH_dom, HLH_DNA-bd_sf, NeuroDiff_E-box_TFs | |
| TCF7L1 | Other/Unknown | no | HMG_box_dom, CTNNB1-bd_N, TCF/LEF | |
| PAK1 | Kinase | yes | 2.7.11.1 | CRIB_dom, Prot_kinase_dom, Ser/Thr_kinase_AS |
Expression context
Cohort genes with no expression data: 0.
4 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 4 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| leukocyte | 1 |
| monocyte | 1 |
| pancreatic ductal cell | 1 |
| embryo | 1 |
| ganglionic eminence | 1 |
| ventricular zone | 1 |
| aorta | 1 |
| popliteal artery | 1 |
| tibial artery | 1 |
| Brodmann (1909) area 23 | 1 |
| endothelial cell | 1 |
| middle temporal gyrus | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| NTNG2 | 173 | broad | marker | pancreatic ductal cell, monocyte, leukocyte |
| TCF3 | 294 | ubiquitous | marker | ganglionic eminence, ventricular zone, embryo |
| TCF7L1 | 230 | ubiquitous | marker | popliteal artery, tibial artery, aorta |
| PAK1 | 272 | ubiquitous | marker | middle temporal gyrus, Brodmann (1909) area 23, endothelial cell |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| PAK1 | 2,780 |
| TCF7L1 | 1,635 |
| NTNG2 | 1,387 |
| TCF3 | 457 |
Structural data
PDB: 3 · AlphaFold-only: 1 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| PAK1 | Q13153 | 41 |
| TCF3 | P15923 | 5 |
| NTNG2 | Q96CW9 | 3 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| TCF7L1 | Q9HCS4 | 52.59 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 57. Enrichment computed across 4 evidence-associated genes (4 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Binding of TCF/LEF:CTNNB1 to target gene promoters | 1 | 285.5× | 0.029 | TCF7L1 |
| RUNX3 regulates WNT signaling | 1 | 285.5× | 0.029 | TCF7L1 |
| CD28 dependent Vav1 pathway | 1 | 219.6× | 0.029 | PAK1 |
| Activation of RAC1 | 1 | 203.9× | 0.029 | PAK1 |
| Repression of WNT target genes | 1 | 178.4× | 0.029 | TCF7L1 |
| Sema3A PAK dependent Axon repulsion | 1 | 167.9× | 0.029 | PAK1 |
| Specification of the neural plate border | 1 | 158.6× | 0.029 | TCF7L1 |
| RHO GTPases Activate ROCKs | 1 | 150.3× | 0.029 | PAK1 |
| Ephrin signaling | 1 | 142.8× | 0.029 | PAK1 |
| G beta:gamma signalling through CDC42 | 1 | 142.8× | 0.029 | PAK1 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 1 | 142.8× | 0.029 | TCF7L1 |
| RHO GTPases activate PAKs | 1 | 135.9× | 0.029 | PAK1 |
| Signal transduction by L1 | 1 | 129.8× | 0.029 | PAK1 |
| CD209 (DC-SIGN) signaling | 1 | 129.8× | 0.029 | PAK1 |
| TGFBR3 expression | 1 | 114.2× | 0.029 | TCF3 |
| VEGFR2 mediated vascular permeability | 1 | 102.0× | 0.029 | PAK1 |
| Myogenesis | 1 | 95.2× | 0.029 | TCF3 |
| Signaling by TGFBR3 | 1 | 92.1× | 0.029 | TCF3 |
| Generation of second messenger molecules | 1 | 86.5× | 0.029 | PAK1 |
| FCERI mediated MAPK activation | 1 | 86.5× | 0.029 | PAK1 |
| RHO GTPases activate PKNs | 1 | 79.3× | 0.029 | PAK1 |
| RHOH GTPase cycle | 1 | 77.2× | 0.029 | PAK1 |
| Beta-catenin independent WNT signaling | 1 | 73.2× | 0.029 | TCF7L1 |
| RHOV GTPase cycle | 1 | 71.4× | 0.029 | PAK1 |
| RHOU GTPase cycle | 1 | 69.6× | 0.029 | PAK1 |
| Transcriptional regulation by RUNX3 | 1 | 68.0× | 0.029 | TCF7L1 |
| EPHB-mediated forward signaling | 1 | 66.4× | 0.029 | PAK1 |
| Smooth Muscle Contraction | 1 | 66.4× | 0.029 | PAK1 |
| Gastrulation | 1 | 64.9× | 0.029 | TCF7L1 |
| RNA Polymerase II Transcription | 2 | 11.3× | 0.029 | TCF3, TCF7L1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of cell proliferation involved in contact inhibition | 1 | 1053.2× | 0.014 | PAK1 |
| postsynaptic specialization assembly | 1 | 1053.2× | 0.014 | NTNG2 |
| B cell lineage commitment | 1 | 842.6× | 0.014 | TCF3 |
| immunoglobulin V(D)J recombination | 1 | 702.2× | 0.014 | TCF3 |
| regulation of neuron projection arborization | 1 | 702.2× | 0.014 | NTNG2 |
| hepatocyte growth factor receptor signaling pathway | 1 | 526.6× | 0.014 | PAK1 |
| positive regulation of microtubule nucleation | 1 | 526.6× | 0.014 | PAK1 |
| protein localization to cytoplasmic stress granule | 1 | 526.6× | 0.014 | PAK1 |
| negative regulation of cell growth involved in cardiac muscle cell development | 1 | 351.1× | 0.019 | PAK1 |
| positive regulation of intracellular estrogen receptor signaling pathway | 1 | 300.9× | 0.019 | PAK1 |
| positive regulation of fibroblast migration | 1 | 280.9× | 0.019 | PAK1 |
| positive regulation of vascular associated smooth muscle cell migration | 1 | 247.8× | 0.019 | PAK1 |
| regulation of Wnt signaling pathway | 1 | 221.7× | 0.019 | TCF7L1 |
| regulation of axonogenesis | 1 | 221.7× | 0.019 | PAK1 |
| positive regulation of insulin receptor signaling pathway | 1 | 210.7× | 0.019 | PAK1 |
| stimulatory C-type lectin receptor signaling pathway | 1 | 183.2× | 0.019 | PAK1 |
| branching morphogenesis of an epithelial tube | 1 | 183.2× | 0.019 | PAK1 |
| Fc-gamma receptor signaling pathway involved in phagocytosis | 1 | 175.5× | 0.019 | PAK1 |
| regulation of DNA-templated transcription | 2 | 15.8× | 0.019 | TCF3, TCF7L1 |
| regulation of neuron migration | 1 | 156.0× | 0.019 | NTNG2 |
| obsolete positive regulation of DNA-binding transcription factor activity | 1 | 150.5× | 0.019 | TCF3 |
| synaptic membrane adhesion | 1 | 145.3× | 0.019 | NTNG2 |
| positive regulation of protein targeting to membrane | 1 | 140.4× | 0.019 | PAK1 |
| regulation of presynapse assembly | 1 | 135.9× | 0.019 | NTNG2 |
| positive regulation of axon extension | 1 | 127.7× | 0.019 | PAK1 |
| regulation of MAPK cascade | 1 | 113.9× | 0.019 | PAK1 |
| positive regulation of cell cycle | 1 | 110.9× | 0.019 | TCF3 |
| regulation of neuron projection development | 1 | 108.0× | 0.019 | NTNG2 |
| positive regulation of vascular associated smooth muscle cell proliferation | 1 | 108.0× | 0.019 | PAK1 |
| establishment of cell polarity | 1 | 95.8× | 0.021 | PAK1 |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 3
Druggability breadth: 1 of 4 evidence-associated genes (25%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| PAK1 | FEDRATINIB |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| PAK1 | 23 | 4 |
| NTNG2 | 0 | 0 |
| TCF3 | 0 | 0 |
| TCF7L1 | 0 | 0 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| FEDRATINIB | 4 | PAK1 |
| NERATINIB | 4 | PAK1 |
| BOSUTINIB | 4 | PAK1 |
| KETOROLAC | 4 | PAK1 |
| MIDOSTAURIN | 4 | PAK1 |
| CURCUMIN | 3 | PAK1 |
| RESVERATROL | 3 | PAK1 |
| LESTAURTINIB | 3 | PAK1 |
| CENISERTIB | 2 | PAK1 |
| ILORASERTIB | 2 | PAK1 |
| LAUROGUADINE | 2 | PAK1 |
| SEPANTRONIUM BROMIDE | 2 | PAK1 |
| DEFOSBARASERTIB | 2 | PAK1 |
| PADNARSERTIB | 2 | PAK1 |
| R-406 | 2 | PAK1 |
| TOZASERTIB | 2 | PAK1 |
| PELITINIB | 2 | PAK1 |
| PF-00562271 | 1 | PAK1 |
| KW-2449 | 1 | PAK1 |
| RG-1530 | 1 | PAK1 |
| MLN-8054 | 1 | PAK1 |
| PF-03758309 | 1 | PAK1 |
| GSK-690693 | 1 | PAK1 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| PAK1 | 401 | Binding:394, Functional:5, ADMET:2 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| PAK1 | 2.7.11.1 | non-specific serine/threonine protein kinase |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| PAK1 | 401 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
23 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| FEDRATINIB | 4 | PAK1 |
| NERATINIB | 4 | PAK1 |
| BOSUTINIB | 4 | PAK1 |
| KETOROLAC | 4 | PAK1 |
| MIDOSTAURIN | 4 | PAK1 |
| CURCUMIN | 3 | PAK1 |
| RESVERATROL | 3 | PAK1 |
| LESTAURTINIB | 3 | PAK1 |
| CENISERTIB | 2 | PAK1 |
| ILORASERTIB | 2 | PAK1 |
| LAUROGUADINE | 2 | PAK1 |
| SEPANTRONIUM BROMIDE | 2 | PAK1 |
| DEFOSBARASERTIB | 2 | PAK1 |
| PADNARSERTIB | 2 | PAK1 |
| R-406 | 2 | PAK1 |
| TOZASERTIB | 2 | PAK1 |
| PELITINIB | 2 | PAK1 |
| PF-00562271 | 1 | PAK1 |
| KW-2449 | 1 | PAK1 |
| RG-1530 | 1 | PAK1 |
| MLN-8054 | 1 | PAK1 |
| PF-03758309 | 1 | PAK1 |
| GSK-690693 | 1 | PAK1 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | PAK1 |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 3 | NTNG2, TCF3, TCF7L1 |
Undrugged target profiles
3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| NTNG2 | 0 | — |
| TCF3 | 0 | — |
| TCF7L1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.